COMP <GO>
MED vs BGS // DIVIDEND YIELD & FCF PAYOUT SAFETY
MEDIFAST INC (NYSE) VS. B&G Foods Inc. (NYSE) • 15-METRIC TALLY: MED 4
— BGS 5
▲ DIVIDEND YIELD & FCF PAYOUT SAFETY LEADER: MED
LAST: $12.26 (-0.16%) • MKT CAP: $137.1M
dividend-safety
0.14%
LAST: $2.26 (+9.71%) • MKT CAP: $183.7M
dividend-safety
0.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MED VS. BGS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MED | BGS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 71.30% | 21.80% | +49.50 | MED | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -10.20% | 3.30% | -13.50 | BGS | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 16.8x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.91% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -3.70% | 5.30% | -9.00 | BGS | /operating-margins <GO> |
| Net Profit Margin | -4.90% | -2.40% | -2.50 | BGS | /net-margins <GO> |
| Revenue Growth (YoY) | -36.00% | -5.40% | -30.60 | BGS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 0.14% | 0.00% | +0.14 | MED | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.71 | 1.24 | +3.47 | MED | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 5/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.3 | 43.2 | +11.10 | MED | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $137.1M | $183.7M | -$46.6M | BGS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MED REV | BGS REV | MED GROSS % | BGS GROSS % | MED FCF | BGS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $385.8M | $1.83B | 71.3% | 21.8% | $1.2M | $70.7M |
| FY 2024 | $602.5M | $1.93B | 73.8% | 21.8% | $17.0M | $103.7M |
| FY 2023 | $1.07B | $2.06B | — | — | $147.7M | $247.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MED // BETA —
BGS // BETA —